EQUITY RESEARCH - ANALYST MEETING

THAILAND / HEALTH CARE SERVICES







BDMS TB



Key takeaways from analyst meeting

BANGKOK DUSIT MEDICAL SERVICES

TARGET PRICE THB34.50 **CLOSE** THB26.50 **UP/DOWNSIDE** +30.2% **TP vs CONSENSUS** +0.7%

Highlights


- We have slightly positive feedback from BDMS's 3Q23 analyst meeting.
- Management revised up their 2023 revenue growth target to 9-10% from 6-8% with an EBITDA margin of 24% (vs 24% in 9M23). This implies revenue growth of 9-13% y-y to THB26.0-26.9b in 4Q23 (vs THB26.7b in 3Q23).
- International patient revenue growth momentum continued in Oct with growth of 19% y-y (vs 19% in Oct). Middle East patient revenue slowed down to 31% y-y (vs 41% y-y in 3Q23), but CLMV patient revenue accelerated to 13% y-y (vs 12% y-y in 3Q23).
- Expect Social Security Office (SSO) registered members to grow from 790k in 2023 to more than 1.0m in 2025. Nine hospitals have currently joined the SSO scheme, and three additional hospitals should join over the next two years.
- Chinese patients have jumped from ninth to fourth rank in terms of revenue contribution (1.9% of total revenue in 9M23), with 49% y-y growth in 9M23 driven by expat patients.
- Movenpick Wellness Resort is currently running at a 60% OCC rate, while the net profit breakeven point is at a 70% OCC rate. Revenue from international customers account for around 40%. BDMS plans to add more clinic services to the hotel such as sleep tests or checkups to attract more international wellness customers next year.

Recommendation

BDMS is trading at 28x 2024E P/E, lower than its five-year average of 34x. Its share price has fallen by 9% since the beginning of this year, in contrast with its earnings which hit a new record high in 3Q23. Thus, we see this as an opportunity to buy the stock.

KEY STOCK DATA

YE Dec (THB m)	2022	2023E	2024E	2025E
Revenue	92,968	100,315	108,779	116,421
Net profit	12,606	13,469	15,295	16,843
EPS (THB)	0.79	0.85	0.96	1.06
vs Consensus (%)	-	(0.1)	4.2	6.5
EBITDA	22,933	24,415	26,856	29,091
Recurring net profit	12,606	13,469	15,295	16,843
Core EPS (THB)	0.79	0.85	0.96	1.06
EPS growth (%)	63.0	6.8	13.6	10.1
Core P/E (x)	33.4	31.3	27.5	25.0
Dividend yield (%)	1.9	1.9	1.9	2.2
EV/EBITDA (x)	18.9	17.5	15.6	14.1
Price/book (x)	4.7	4.4	4.1	3.8
Net debt/Equity (%)	9.2	1.3	(7.0)	(14.4)
ROE (%)	14.5	14.5	15.4	15.8




Share price performance	1 Month	3 Month	12 Month
Absolute (%)	(2.8)	(6.2)	(8.6)
Relative to country (%)	(1.5)	1.3	4.2
Mkt cap (USD m)			12,010
3m avg. daily turnover (USD m)			39.4
Free float (%)			70
Major shareholder		Thai N\	/DR (14%)
12m high/low (THB)		3	1.00/25.00
Issued shares (m)			15,892.00

Sources: Bloomberg consensus; FSSIA estimates




Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

Exhibit 1: Non-Covid Thai patient revenue, quarterly



Source: BDMS

Exhibit 3: Utilisation rate



Source: BDMS

Exhibit 5: Strong trend of international patient growth






Exhibit 2: International patient revenue, quarterly




Source: BDMS

Exhibit 4: EBITDA margin trend, quarterly



Source: BDMS

Exhibit 6: Revenue contribution by nationality as of 9M23



Source: BDMS Source: BDMS

Financial Statements

Bangkok Dusit Medical Services

Profit and Loss (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
Revenue	75,514	92,968	100,315	108,779	116,421
Cost of goods sold	(49,462)	(58,329)	(62,761)	(67,590)	(72,059)
Gross profit	26,052	34,638	37,555	41,189	44,362
Other operating income	-	-	-	-	-
Operating costs	(15,029)	(17,655)	(19,351)	(20,712)	(21,934)
Operating EBITDA	17,345	22,933	24,415	26,856	29,091
Depreciation	(6,321)	(5,950)	(6,211)	(6,378)	(6,663)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	11,023	16,984	18,204	20,478	22,428
Net financing costs	(655)	(552)	(558)	(469)	(394)
Associates	21	42	26	28	31
Recurring non-operating income	26	50	34	38	42
Non-recurring items	200	0	0	0	0
Profit before tax	10,594	16,481	17,680	20,047	22,075
Tax	(2,103)	(3,227)	(3,531)	(4,004)	(4,409)
Profit after tax	8,490	13,254	14,149	16,043	17,666
Minority interests	(554)	(648)	(680)	(748)	(823)
Preferred dividends	-	. ,	. ,	. ,	
Other items	-	-	-	-	-
Reported net profit	7,936	12,606	13,469	15,295	16,843
Non-recurring items & goodwill (net)	(200)	0	0	0	0
Recurring net profit	7,736	12,606	13,469	15,295	16,843
Per share (THB)					
Recurring EPS *	0.49	0.79	0.85	0.96	1.06
Reported EPS	0.50	0.79	0.85	0.96	1.06
DPS	0.80	0.50	0.50	0.51	0.58
Diluted shares (used to calculate per share data)	15,892	15,892	15,892	15,892	15,892
Growth					
Revenue (%)	9.3	23.1	7.9	8.4	7.0
Operating EBITDA (%)	16.1	32.2	6.5	10.0	8.3
Operating EBIT (%)	29.3	54.1	7.2	12.5	9.5
Recurring EPS (%)	28.0	63.0	6.8	13.6	10.1
Reported EPS (%)	10.0	58.8	6.8	13.6	10.1
Operating performance					
Gross margin inc. depreciation (%)	34.5	37.3	37.4	37.9	38.1
Gross margin exc. depreciation (%)	42.9	43.7	43.6	43.7	43.8
Operating EBITDA margin (%)	23.0	24.7	24.3	24.7	25.0
Operating EBIT margin (%)	14.6	18.3	18.1	18.8	19.3
Net margin (%)	10.2	13.6	13.4	14.1	14.5
Effective tax rate (%)	20.3	19.6	20.0	20.0	20.0
Dividend payout on recurring profit (%)	164.7	63.0	59.0	52.8	54.5
Interest cover (X)	16.9	30.8	32.7	43.8	57.0
Inventory days	16.3	14.7	14.8	14.8	14.9
Debtor days	39.4	38.5	38.1	35.2	32.9
Creditor days	40.1	39.1	41.4	41.4	41.7
Operating ROIC (%)	10.6	15.8	16.2	18.4	20.4
ROIC (%)	8.5	12.7	13.1	14.8	16.3
ROE (%)	9.0	14.5	14.5	15.4	15.8
ROA (%)	6.7	10.1	10.1	10.9	11.2
* Pre exceptional, pre-goodwill and fully diluted					
		0000	2023E	2024E	2025E
Revenue by Division (THB m)	2021	2022	2023E	2024E	2025E
Revenue by Division (THB m) Thai patient revenue International patient revenue	2021 58,500 12,841	67,286 21,248	68,038 27,623	73,507 30,385	79,081 32,208

Sources: Bangkok Dusit Medical Services; FSSIA estimates

Financial Statements

Bangkok Dusit Medical Services

Ballykok Busit Medical Services					
Cash Flow (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
Recurring net profit	7,736	12,606	13,469	15,295	16,843
Depreciation	6,321	5,950	6,211	6,378	6,663
Associates & minorities	-	-	-		-
Other non-cash items	997	1,275	680	748	823
Change in working capital	(980)	720	940	1,072	966
Cash flow from operations	14,074	20,551	21,300	23,493	25,295
Capex - maintenance	(4,235)	(14,953)	(6,019)	(6,527)	(6,985)
Capex - new investment	-	-	-	-	
Net acquisitions & disposals	(58)	(386)	0	0	0
Other investments (net)	- (4 000)	-	-	-	-
Cash flow from investing	(4,293)	(15,340)	(6,019)	(6,527)	(6,985)
Dividends paid	(12,738)	(7,943)	(7,946)	(8,081)	(9,177)
Equity finance	(5.440)	0	0	0	(500)
Debt finance	(5,416)	4,764	(2,000)	(500)	(500)
Other financing cash flows	75 (49.070)	299	(0.046)	0 (9 594)	(0.677)
Cash flow from financing	(18,079)	(2,880)	(9,946)	(8,581)	(9,677)
Non-recurring cash flows	0	0	0	0	0
Other adjustments Net other adjustments	0	0	0	0	0
Novement in cash	(8,298)	2,330	5,335	8,385	8,633
Free cash flow to firm (FCFF)	10,509.69	5,842.84	15,981.37	17,627.65	18,977.14
Free cash flow to equity (FCFE)	4,439.73	10,273.66	13,280.96	16,465.99	17,810.13
	4,439.73	10,273.00	13,200.90	10,405.99	17,010.13
Per share (THB)	0.66	0.27	1.01	1 11	1 10
FCFF per share	0.66	0.37	1.01	1.11	1.19
FCFE per share Recurring cash flow per share	0.28 0.95	0.65 1.25	0.84 1.28	1.04 1.41	1.12 1.53
Balance Sheet (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
Tangible fixed assets (gross)	142,630	155,412	161,431	167,958	174,943
Less: Accumulated depreciation	(59,725)	(63,503)	(69,714)	(76,092)	(82,755)
Tangible fixed assets (net)	82,905	91,909	91,717	91,866	92,188
ntangible fixed assets (net)	18,828	19,160	19,160	19,160	19,160
ong-term financial assets	-	-	-	-	-
nvest. in associates & subsidiaries	1,600	1,986	1,986	1,986	1,986
Cash & equivalents	12,641	14,972	20,307	28,691	37,325
A/C receivable	9,131	10,484	10,484	10,484	10,484
nventories	2,005	2,211	2,387	2,584	2,761
Other current assets	624	132	142	154	165
Current assets	24,401	27,799	33,320	41,914	50,735
Other assets	720	689	689	689	689
Total assets	128,454	141,543	146,872	155,615	164,758
Common equity	83,845	89,879	95,402	102,615	110,282
Minorities etc.	3,920	3,834	4,514	5,262	6,086
Total shareholders' equity	87,765	93,713	99,916	107,878	116,368
Long term debt	18,753	23,062	21,062	20,562	20,062
Other long-term liabilities	9,442	10,032	10,032	10,032	10,032
ong-term liabilities	28,196	33,094	31,094	30,594	30,094
A/C payable	5,035	6,176	6,668	7,217	7,711
Short term debt	76	532	532	532	532
Other current liabilities	7,382	8,028	8,663	9,394	10,053
Current liabilities	12,493	14,736	15,862	17,143	18,296
Fotal liabilities and shareholders' equity	128,454	141,543	146,872	155,615	164,758
Net working capital	(657)	(1,377)	(2,316)	(3,388)	(4,354)
nvested capital	103,396	112,367	111,235	110,313	109,669
Includes convertibles and preferred stock which is be	*	112,007	111,200	110,010	100,000
Per share (THB)					
Book value per share	5.28	5.66	6.00	6.46	6.94
Fangible book value per share	4.09	4.45	4.80	5.25	5.73
	4.09	4.45	4.00	5.25	5.75
Financial strength	7.1	0.0	4.0	(7.0)	/4.4.41
Vet debt/equity (%)	7.1	9.2	1.3	(7.0)	(14.4)
Net debt/total assets (%)	4.8	6.1	0.9	(4.9)	(10.2)
Current ratio (x)	2.0	1.9	2.1	2.4	2.8
CF interest cover (x)	7.8	19.6	24.8	36.1	46.2
/aluation	2021	2022	2023E	2024E	2025E
Recurring P/E (x) *	54.4	33.4	31.3	27.5	25.0
Recurring P/E @ target price (x) *	70.9	43.5	40.7	35.8	32.6
Reported P/E (x)	53.1	33.4	31.3	27.5	25.0
Dividend yield (%)	3.0	1.9	1.9	1.9	2.2
Price/book (x)	5.0	4.7	4.4	4.1	3.8
Price/tangible book (x)	6.5	6.0	5.5	5.0	4.6
	24.0	18.9	17.5	15.6	14.1
EV/EBITDA (x) **	24.9				
* *	32.2	24.5	22.7	20.3	18.5
EV/EBITDA (x) ** EV/EBITDA @ target price (x) ** EV/invested capital (x)			22.7 3.8	20.3 3.8	18.5 3.7

Sources: Bangkok Dusit Medical Services; FSSIA estimates

Bangkok Dusit Medical Serv (BDMS TB)

FSSIA ESG rating

★ ★ ★ ★

Exhibit 7: FSSIA ESG score implication

74.00 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
****	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 8: ESG – peer comparison

	FSSIA			Dome	estic ratings			Global ratings						Bloomberg		
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score	
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17	
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94	
BCH	39.71			-	4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60	
BDMS	74.00	Υ	Υ	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92	
BH	51.21			-	4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79	
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24	
PR9	54.08		Υ	Υ	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90	
PRINC	18.00			-	4.00	4.00	Certified									
RAM	11.75			-	3.00			High								
THG	18.75			-	5.00	5.00		High								
VIBHA	20.88				4.00	3.00	Declared	High					17.00			

 $Sources: \underline{SETTRADE.com}; \ FSSIA's \ compilation$

Exhibit 9: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	1.08	1.05	2.21	2.76	3.74	3.77	3.76	3.45
BESG environmental pillar score	0.00	0.00	2.04	4.49	4.17	3.84	3.24	2.25
BESG social pillar score	0.14	0.14	1.24	1.48	3.40	3.53	3.54	3.59
BESG governance pillar score	4.56	4.40	4.37	4.19	4.03	4.13	4.51	4.12
ESG disclosure score	32.33	32.33	46.90	47.34	57.35	57.69	58.34	58.92
Environmental disclosure score	0.00	0.00	22.74	24.07	52.31	52.31	54.27	56.00
Social disclosure score	13.21	13.21	34.22	34.22	36.03	37.06	37.06	37.06
Governance disclosure score	83.59	83.59	83.59	83.59	83.59	83.59	83.59	83.59
Environmental								
Emissions reduction initiatives	No							
Climate change policy	No	No	No	No	Yes	Yes	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No							
GHG scope 1	_	_	3	4	9	35	9	34
GHG scope 2 location-based	_	_	91	92	98	94	96	209
GHG Scope 3	_	_	_	_	_	_	_	_
Carbon per unit of production	_	_	_	_	_	_	_	_
Biodiversity policy	No							
Energy efficiency policy	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Total energy consumption	_	_	143	145	152	147	194	497
Renewable energy use	_	_	_	_	_	_	_	5
Electricity used	_	_	143	145	152	147	192	417
Fuel used - natural gas	_	_	_	_	_	_	_	_

Sources: Bloomberg; FSSIA's compilation

Exhibit 10: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No	No	No	No	No	No
Waste reduction policy	No	No	No	Yes	Yes	Yes	Yes	Yes
Hazardous waste	_	_	1	2	2	2	3	5
Total waste	_	_	6	7	7	5	9	13
Waste recycled	_	_	0	1	1	0	1	2
Waste sent to landfills	_	_	_	_	_	_	3	5
Environmental supply chain management	No	No	No	No	Yes	Yes	Yes	Yes
Water policy	No	No	No	Yes	Yes	Yes	Yes	Yes
Water consumption	_	_	354	358	388	332	472	754
Social								
Human rights policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Policy against child labor	No	No	No	No	No	Yes	Yes	Yes
Quality assurance and recall policy	No	No	No	No	Yes	Yes	Yes	Yes
Consumer data protection policy	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Gender pay gap breakout	No	No	No	No	No	No	No	No
Pct women in workforce	_	_	82	82	82	82	83	83
Pct disabled in workforce	_	_	_	_	_	_	_	_
Business ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Health and safety policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lost time incident rate - employees	_	_	0	0	0	0	0	1
Total recordable incident rate - employees	_	_	2	2	2	1	1	1
Training policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Fair remuneration policy	No	No	No	No	No	No	No	No
Number of employees – CSR	33,456	36,989	37,505	38,803	40,298	36,254	36,344	40,495
Employee turnover pct			18	19	19	17	16	20
Total hours spent by firm - employee training	568,960	588,890	795,330	547,592	784,625	476,816	437,209	1,417,320
Social supply chain management	No	No	7 55,556 No	No	Yes	Yes	Yes	Yes
Governance	140	110	140	110	100	100	. 00	100
Board size	15	14	13	14	14	16	18	17
No. of independent directors (ID)	7	6	6	6	6	7	7	7
No. of women on board	2	1	1	1	1	2	2	2
No. of non-executive directors on board	9	7	6	8	9	9	9	9
Company conducts board evaluations	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
No. of board meetings for the year	13	13	14	12	13	12	12	12
5	95	94	98	97	98	98	97	100
Board meeting attendance pct	3	3	3	3	3	3	3	3
Board duration (years)								
Director share ownership guidelines	No 45	No 42	No 42	No	No 45	No 46	No	No 49
Age of the oldest director	45	42	43	44	45	46	47	48
Age of the oldest director	83	84	85	86	87	88	89 •	90
No. of executives / company managers	4	5	5	5	6	7	5	5
No. of female executives	1	1	1	2	1	2	2	2
Executive share ownership guidelines	No	No	No	No	No	No	No	No
Size of audit committee	3	3	3	3	3	3	3	3
No. of ID on audit committee	3	3	3	3	3	3	3	3
Audit committee meetings	10	9	10	7	10	6	6	6
Audit meeting attendance %	100	100	100	100	97	100	100	100
Size of compensation committee	4	4	4	4	4	3	3	3
No. of ID on compensation committee	3	3	3	2	2	2	2	2
No. of compensation committee meetings	3	1	4	4	3	4	4	3
Compensation meeting attendance %	100	100	100	100	100	100	100	100
Size of nomination committee	4	4	4	4	4	3	3	3
No. of nomination committee meetings	3	1	4	4	3	4	4	3
Nomination meeting attendance %	100	100	100	100	100	100	100	100
Sustainability governance								
Verification type	No	No	No	No	No	No	No	No

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

	or 200 dooring								
ESG score	Methodology			Rating					
The Dow Jones Sustainability ndices (<u>DJSI</u>) By S&P Global	process based on the of from the annual S&P G	es a transparent, rules-based companies' Total Sustainabili Global Corporate Sustainabilit ompanies within each industry	ity Scores resulting ty Assessment (CSA).	ESG Score of	Assessment less than 45 ny are disqu	(CSA) for DJS % of the S&P (alified. The co	I. Companie: Global ESG :	orporate s with an S&P (Score of the hig the DJSI indice	ghest
Sustainability Investment List (THSI) by The Stock Exchange of Thailand (SET)	managing business wit Candidates must pass 1) no irregular trading of float of >150 sharehold up capital. Some key of 70%; 2) independent of wrongdoing related to	nsibility in Environmental and th transparency in Governand the preemptive criteria, with of the board members and exiders, and combined holding natisqualifying criteria include: 1 directors and free float violatic CG, social & environmental in 5) earnings in red for > 3 year	ce, updated annually. two crucial conditions: xecutives; and 2) free nust be >15% of paid- 1) CG score of below on; 3) executives' mpacts; 4) equity in	To be eligible for <u>THSI inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against th nature of the relevant industry and materiality. <u>SETTHSI Index</u> is extended from the THSI companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight maximum, and no cap for number of stocks.					
oy Thai nstitute of Directors Association Thai IOD)	annually by the Thai IC	ength in sustainable developn DD, with support from the Sto esults are from the perspectiv tions.	ck Exchange of	Good (80-89), and not rated t equitable treat	3 for Good (or scores be ment of shar 25%); 4) dis	70-79), 2 for Fa elow 50. Weight eholders (weig	air (60-69), 1 tings include _I ht 25% com	100), 4 for Very for Pass (60-6 : 1) the rights; 2 bined); 3) the ro %); and 5) boar	9), 2) an ole o
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are incorpora transparent and sufficio out of five the CG com assessment criteria co the meeting date (45% advance circulation of suff rights can be exercised. Ti transparency and verifiabil	to which shareholders' rights ated into business operations ently disclosed. All form imporponents to be evaluated anniver AGM procedures before to,), and after the meeting (10% ficient information for voting; and 2 he second assesses 1) the ease of lity; and 3) openness for Q&A. The ald contain discussion issues, resolutions.	s and information is ortant elements of two ually. The the meeting (45%), at (6). (The first assesses 1)? facilitating how voting of attending meetings; 2) e third involves the					cellent (100), 4 ir scores below	
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishment of key or policies. The Certificati (Companies deciding to be Declaration of Intent to kic. Certification, including risk	the Checklist include corruption ontrols, and the monitoring and ion is good for three years. ecome a CAC certified member stok off an 18-month deadline to sub assessment, in place of policy and establishment of whistleblowing to all stakeholders.)	nd developing of art by submitting a mit the CAC Checklist for ad control, training of	passed Check approvals who	list will move se members	for granting ce	ertification by hly respecte	e professionals. the CAC Cour d individuals in	ncil
Morningstar Sustainalytics	based on an assessme risk is unmanaged. Sou	G risk rating provides an ove ent of how much of a compan urces to be reviewed include corpo	ny's exposure to ESG orate publications and	A company's E more risk is un				anaged risk. Th d.	e
		d other media, NGO reports/webs dback, ESG controversies, issuer t r reviews.		NEGL 0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+	
ESG Book	positioned to outperfor the principle of financia helps explain future ris	ies sustainable companies them over the long term. The mal materiality including informations with a material to performance. Mat is with higher materiality and larterly basis.	ethodology considers ation that significantly teriality is applied by		nateriality-ba		he score is s	caled between	0
<u>MSCI</u>		n to measure a company's ma rs and laggards according to							gy to
	AAA 8.571-10	Leader:	leading its industry in n	nanaging the most s	ignificant ESC	risks and opport	unities		
	AA 7.143-8								
	A 5.714-7 BBB 4.286-5		a mixed or unexception	nal track record of m	anaging the n	nost significant ES	G risks and o	portunities relativ	/e to
	BB 2.857-4	•	industry peers						
	B 1.429-2	2.856	In make - the test of the	and an ite total	numa em d f d	- to more	ifinant FCC :	lea.	
	CCC 0.000-1	Laggard:	lagging its industry bas	eu on its nigh expo	sure and failur	e to manage sign	ilicant ESG ris	KS	
Moody's ESG solutions	believes that a compar	degree to which companies in integrating ESG factors intue for shareholders over the r	to its business model an						
Refinitiv ESG rating	based on publicly avail	ntly and objectively measure lable and auditable data. The G data publicly. (Score ratings a	score ranges from 0 to	100 on relative E	SG perform	ance and insuf	fficient degre		
S&P Global		Score is a relative score mea within the same industry clas				nt of ESG risks	s, opportuniti	es, and impacts	3
Bloomberg	ESG Score	Bloomberg score evalua							
		score is based on Bloor of Pillar Scores, where t							

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
24-Nov-2020	BUY	27.00	24-Jun-2021	BUY	29.00	06-Oct-2022	BUY	33.00
11-May-2021	BUY	28.00	19-Apr-2022	BUY	31.00	08-Jan-2023	BUY	34.50

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Bangkok Dusit Medical Services	BDMS TB	THB 26.50	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 17-Nov-2023 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.